Peptomer Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
5
Peptomer Therapeutics General Information
Description
Operator of a therapeutics development firm intended to combat antimicrobial resistance through novel alternatives to antibiotics. The company offers antimicrobial peptides, oligomers, oligomer-peptide hybrids, and antimicrobial formulations, enabling healthcare providers and pharmaceutical companies to treat drug-resistant bacterial and fungal infections and improve antimicrobial efficacy.
Contact Information
Website
www.peptomertherapeutics.comCorporate Office
- Lab-7, BSC BioNEST Bio-Incubator, 3rd milestone
- Faridabad-Gurgaon Road, expressway
- Faridabad, Haryana 121001
- India
Corporate Office
- Lab-7, BSC BioNEST Bio-Incubator, 3rd milestone
- Faridabad-Gurgaon Road, expressway
- Faridabad, Haryana 121001
- India
Peptomer Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 5. Accelerator/Incubator | Completed | Startup | ||||
| 4. Accelerator/Incubator | Completed | Startup | ||||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Accelerator/Incubator | $173K | Completed | Startup | |||
| 1. Capitalization | $173K | $173K | Completed | Startup |
Peptomer Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Peptomer Therapeutics Patents
Peptomer Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4525827-A1 | Synthetic cationic peptidomimetics, their derivatives and preparation thereof along with compositions for various medical applications | Pending | 24-Apr-2022 | ||
| EP-4525827-A4 | Synthetic cationic peptidomimetics, their derivatives and preparation thereof along with compositions for various medical applications | Pending | 24-Apr-2022 | ||
| US-20250352656-A1 | Synthetic cationic peptidomimetics, their derivatives and preparation thereof along with compositions for various medical applications | Pending | 24-Apr-2022 | ||
| WO-2023209728-A1 | Synthetic cationic peptidomimetics, their derivatives and preparation thereof along with compositions for various medical applications | Inactive | 24-Apr-2022 | A61K47/6455 |
Peptomer Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Peptomer Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BIRAC | Government | |||
| BSC BioNEST Bio-Incubator | Accelerator/Incubator | |||
| NaaViC | Accelerator/Incubator | |||
| NIDHI Prayas | Accelerator/Incubator | |||
| Startup Haryana | Accelerator/Incubator |
Peptomer Therapeutics FAQs
-
When was Peptomer Therapeutics founded?
Peptomer Therapeutics was founded in 2020.
-
Where is Peptomer Therapeutics headquartered?
Peptomer Therapeutics is headquartered in Faridabad, India.
-
What is the size of Peptomer Therapeutics?
Peptomer Therapeutics has 6 total employees.
-
What industry is Peptomer Therapeutics in?
Peptomer Therapeutics’s primary industry is Drug Discovery.
-
Is Peptomer Therapeutics a private or public company?
Peptomer Therapeutics is a Private company.
-
What is Peptomer Therapeutics’s current revenue?
The current revenue for Peptomer Therapeutics is .
-
How much funding has Peptomer Therapeutics raised over time?
Peptomer Therapeutics has raised $173K.
-
Who are Peptomer Therapeutics’s investors?
BIRAC, BSC BioNEST Bio-Incubator, NaaViC, NIDHI Prayas, and Startup Haryana have invested in Peptomer Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
